subject: Paxil Readies $3 Billion Disbursement To Settle Court Cases [print this page] Based on an article in the Washington Post, GlaxoSmithKline(GSK) agrees to disburse $3 billion to settle US lawsuits. This amount is for the resolution of unsettled legal cases in the US, pertaining to illegal promotion of the companys prescription drugs, questionable Medicaid rebates, and issues surrounding Avandia, the popular diabetes drug that has been shown to cause an increased risk of heart attacks.
GSK is also the maker of Paxil, an antidepressant drug belonging in class known as selective serotonin reuptake inhibitors (SSRI). New data analysis, however, showed that antidepressants like Paxil may not be the best way in treating depression. This is mainly because of its alleged harmful effects including life-threatening ones. Both the Psychotherapy and Psychosomatics and the Medical News Today published articles about this analysis.
With the many public advisories from US Food and Drug Administration (FDA), people experiencing depression should consider another way of treating it aside from taking Paxil which has been persistently accused of causing dangerous side effects. Other than the clinical findings and research studies, reports from patients showed that Paxil has caused severe damages on their lives in general and health in particular. These reports are manifested through the Paxil lawsuits charged against GSK.
Paxil has been the object of litigation due to the various harms it caused the patients, including birth defects, suicide, abnormal mood shifts, unusual personality changes, hallucination, psychosis, insomnia, hostility, agitation, self-harm and other acts of violence.
Several Paxil lawsuits have been filed to recover damages for patients who committed suicide while taking Paxil. The litigation argues that GSK failed to warn to doctors and consumers about the dangers of taking Paxil. One class action in California implicated the company of restricting the information about the side effects of Paxil from the public.
GlaxoSmithKline was also accused by US governmental institutions of illegally intervening with the release of a generic version of Paxil. Because of this, other states paid more for the antidepressant drug in their health programs. In 2006, the company agreed to pay $14 million in settlement of the conflict, to be divided among the affected states.
Also, many women who have given birth to children with Paxil birth defects have filed lawsuits against GSK, alleging that it should have informed them of the dangers before they became pregnant. Those qualified for compensation for the damages they experienced due to Paxil may seek legal advice for detailed information on Paxil lawsuits.
